Estimation and comparison of carbamazepine population pharmacokinetics using dried blood spot and plasma concentrations from people with epilepsy: The clinical implication Sing Teang Kong, BPharm1

Journal of Clinical Pharmacology

Volumn 54, Issue 2, 2014, Pages 225-233

  Lim, Shih Hui ^b,c,d   Chan, Eli ^a   Ho, Paul C ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b SINGAPORE GENERAL HOSPITAL   (Singapore)

^c NATIONAL NEUROSCIENCE INSTITUTE   (Singapore)

^d DUKE NUS MEDICAL SCHOOL   (Singapore)

Author keywords

Carbamazepine; Dried blood spot; Epilepsy; Non linear mixed effects modelling; Plasma; Population pharmacokinetics

Indexed keywords

CARBAMAZEPINE; ANTICONVULSIVE AGENT; VALPROIC ACID;

ADULT; AGED; ARTICLE; DRIED BLOOD SPOT TESTING; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DETERMINATION; DRUG ELIMINATION; DRUG MONITORING; EPILEPSY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; POPULATION MODEL; YOUNG ADULT; BIOLOGICAL MODEL; BLOOD; COMPARATIVE STUDY; CROSS-SECTIONAL STUDY; DRUG COMBINATION; RETROSPECTIVE STUDY;

ADULT; AGED; ANTICONVULSANTS; CARBAMAZEPINE; CROSS-SECTIONAL STUDIES; DRIED BLOOD SPOT TESTING; DRUG MONITORING; DRUG THERAPY, COMBINATION; EPILEPSY; FEMALE; HUMANS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; RETROSPECTIVE STUDIES; VALPROIC ACID; YOUNG ADULT;

EID: 84895773315     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.170     Document Type: Article

References (44)

1. Patsalos PN, Duncan JS. Antiepileptic drugs. A review of clinically significant drug interactions. Drug Saf. 1993;9:156-184.
2. Ketter TA, Post RM, Worthington K. Principles of clinically important drug interactions with carbamazepine. Part II. J Clin Psychopharmacol. 1991;11:306-313.
3. Bernus I, Dickinson RG, Hooper WD, Eadie MJ. Early stage autoinduction of carbamazepine metabolism in humans. Eur J Clin Pharmacol. 1994;47:355-360.
4. Liu H, Delgado MR. Influence of sex, age, weight, and carbamazepine dose on serum concentrations, concentration ratios, and level/ dose ratios of carbamazepine and its metabolites. Ther Drug Monit. 1994;16:469-476.
5. Liu H, Delgado MR. Improved therapeutic monitoring of drug interactions in epileptic children using carbamazepine polytherapy. Ther Drug Monit. 1994;16:132-138.
6. Garver DL, Dekirmenjian H, Davis JM, Casper R, Ericksen S. Neuroleptic drug levels and therapeutic response: preliminary observations with red blood cell bound butaperazine. Am J Psychiatry. 1977;134:304-307.
7. Casper R, Garver DL, Dekirmenjian H, Chang S, Davis JM. Phenothiazine levels in plasma and red blood cells. Their relationship to clinical improvement in schizophrenia. Arch Gen Psychiatry. 1980;37:301-305.
8. Svensson C, Nyberg G, Axelsson R, Martensson E. Concentrations of thioridazine and thioridazine metabolites in erythrocytes. Psychopharmacology (Berl). 1986;89:291-292.
9. Lim SH, See SJ, Wong PS, Lim SH. Cost of antiepileptic drug monotherapies and combination therapies at a tertiary referral hospital in Singapore. Epilepsia. 2012;53:194.
10. Summers B, Summers RS. Carbamazepine clearance in paediatric epilepsy patients. Influence of body mass, dose, sex and comedication. Clin Pharmacokinet. 1989;17:208-216.
11. Graves NM, Brundage RC, Wen Y, et al. Population pharmacokinetics of carbamazepine in adults with epilepsy. Pharmacotherapy. 1998;18:273-281.
12. Bondareva IB, Jelliffe RW, Gusev EI, Guekht AB, Melikyan EG, Belousov YB. Population pharmacokinetic modelling of carbamazepine in epileptic elderly patients: implications for dosage. J Clin Pharm Ther. 2006;31:211-221.
13. Ahmed GF, Brundage RC, Marino SE, et al. Population pharmacokinetics of unbound and total drug concentrations following intravenously administered carbamazepine in elderly and younger adult patients with epilepsy. J Clin Pharmacol. 2013;53:276-284.
14. Jiao Z, Zhong MK, Shi XJ, Hu M, Zhang JH. Population pharmacokinetics of carbamazepine in Chinese epilepsy patients. Ther Drug Monit. 2003;25:279-286.
15. Chan E, Lee HS, Hue SS. Population pharmacokinetics of carbamazepine in Singapore epileptic patients. Br J Clin Pharmacol. 2001;51:567-576.
16. Kwan P, Arzimanoglou A, Berg AT, et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc task force of the ILAE commission on therapeutic strategies. Epilepsia. 2010;51: 1069-1077.
17. Bertilsson L, Tomson T. Clinical pharmacokinetics and pharmacological effects of carbamazepine and carbamazepine-10,11-epoxide. An update. Clin Pharmacokinet. 1986;11:177-198.
18. Gray AL, Botha JH, Miller R. A model for the determination of carbamazepine clearance in children on mono-and polytherapy. Eur J Clin Pharmacol. 1998;54:359-362.
19. Sherwin CM, Kiang TK, Spigarelli MG, Ensom MH. Fundamentals of population pharmacokinetic modelling: validation methods. Clin Pharmacokinet. 2012;51:573-590.
20. Vucicevic K, Miljkovic B, Velickovic R, Pokrajac M, Mrhar A, Grabnar I. Population pharmacokinetic model of carbamazepine derived from routine therapeutic drug monitoring data. Ther Drug Monit. 2007;29:781-788.
21. Yukawa E, Aoyama T. Detection of carbamazepine drug interaction by multiple peak approach screening using routine clinical pharmacokinetic data. J Clin Pharmacol. 1996;36:752-759.
22. Battino D, Bossi L, Croci D, et al. Carbamazepine plasma levels in children and adults: influence of age, dose, and associated therapy. Ther Drug Monit. 1980;2:315-322.
23. Rambeck B, May T, Juergens U. Serum concentrations of carbamazepine and its epoxide and diol metabolites in epileptic patients: the influence of dose and comedication. Ther Drug Monit. 1987;9:298-303.
24. Furlanut M, Montanari G, Bonin P, Casara GL. Carbamazepine and carbamazepine-10,11-epoxide serum concentrations in epileptic children. J Pediatr. 1985;106:491-495.
25. Feuer G. Action of pregnancy and various progesterones on hepatic microsomal activites. Drug Metab Rev. 1979;9:147-169.
26. Bonneton J, Genton P, Mesdjian E. Distribution of carbamazepine and its epoxide in blood compartments in adolescent and adult epileptic patients. Biopharm Drug Dispos. 1992;13:411-416.
27. Jiao Z, Shi XJ, Zhao ZG, Zhong MK. Population pharmacokinetic modeling of steady state clearance of carbamazepine and its epoxide metabolite from sparse routine clinical data. J Clin Pharm Ther. 2004;29:247-256.
28. Baciewicz AM. Carbamazepine drug interactions. Ther Drug Monit. 1986;8:305-317.
29. Chang SL, Levy RH. Inhibitory effect of valproic acid on the disposition of carbamazepine and carbamazepine-10,11-epoxide in the rat. Drug Metab Dispos. 1986;14:281-286.
30. El Desoky ES, Sabarinath SN, Hamdi MM, Bewernitz M, Derendorf H. Population pharmacokinetics of steady-state carbamazepine in Egyptian epilepsy patients. J Clin Pharm Ther. 2012;37:352-355.
31. Riva R, Contin M, Albani F, et al. Free and total plasma concentrations of carbamazepine and carbamazepine-10,11-epoxide in epileptic patients: diurnal fluctuations and relationship with side effects. Ther Drug Monit. 1984;6:408-413.
32. Riva R, Albani F, Ambrosetto G, et al. Diurnal fluctuations in free and total steady-state plasma levels of carbamazepine and correlation with intermittent side effects. Epilepsia. 1984;25:476-481.
33. Riva R, Contin M, Albani F, et al. Lateral gaze nystagmus in carbamazepine-treated epileptic patients: correlation with total and free plasma concentrations of parent drug and its 10,11-epoxide metabolite. Ther Drug Monit. 1985;7:277-282.
34. Tomson T. Interdosage fluctuations in plasma carbamazepine concentration determine intermittent side effects. Arch Neurol. 1984;41:830-834.
35. Tsanaclis LM, Wilson JF. Comparison by external quality assessment of performance of analytical systems for measurement of therapeutic drugs in serum. Ther Drug Monit. 1997;19:420-426.
36. Shen S, Elin RJ, Soldin SJ. Characterization of cross reactivity by carbamazepine 10,11-epoxide with carbamazepine assays. Clin Biochem. 2001;34:157-158.
37. Bonneton J, Iliadis A, Genton P, Dravet C, Viallat D, Mesdjian E. Steady state pharmacokinetics of conventional versus controlledrelease carbamazepine in patients with epilepsy. Epilepsy Res. 1993;14:257-263.
38. Schaffler L, Bourgeois BF, Luders HO. Rapid reversibility of autoinduction of carbamazepine metabolism after temporary discontinuation. Epilepsia. 1994;35:195-198.
39. DBS Technical Tips. Whatman part of GE healthcare, 2011 (Accessed 15 August 2013, at https://promo.gelifesciences.com/NA/ k11286/misc/fta/Practical- tips-for-dried-blood-spot-analysis.pdf).
40. Edelbroek PM, van der Heijden J, Stolk LM. Dried blood spot methods in therapeutic drug monitoring: methods, assays, and pitfalls. Ther Drug Monit. 2009;31:327-336.
41. Mei JV, Alexander JR, Adam BW, Hannon WH. Use of filter paper for the collection and analysis of human whole blood specimens. J Nutr. 2001;131:1631S-1636S.
42. Zanet DL, Saberi S, Oliveira L, Sattha B, Gadawski I, Cote HC. Blood and dried blood spot telomere length measurement by qPCR: assay considerations. PLoS ONE. 2013;8:e57787.
43. Leichtle AB, Ceglarek U, Witzigmann H, Gabel G, Thiery J, Fiedler GM. Potential of dried blood self-sampling for cyclosporine c(2) monitoring in transplant outpatients. J Transplant. 2010; 2010(20):1918.
44. WilhelmAJ, Klijn A, den Burger JC, et al. Clinical validation of dried blood spot sampling in therapeutic drugmonitoring of ciclosporinAin allogeneic stem cell transplant recipients: direct comparison between capillary and venous sampling. Ther Drug Monit. 2013;35:92-95.